Author

Adam David Durbin

St. Jude Children's Research HospitalORCID 0000-0002-5472-9847Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1

Frequent Co-Authors

Kimberly StegmaieriD· 3 shared Brian J. AbrahamiD· 2 shared Francisca VázqueziD· 2 shared Jun QiiD· 2 shared Mark W. ZimmermaniD· 2 shared Neekesh V. DhariaiD· 2 shared A Herman· 1 shared A Robichaud· 1 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Kimberly StegmaierORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Annika L. Gustafson, Stephanie Nance, Berkley E. Gryder, Noha A.M. Shendy, Lars Wick, Grace B. McKay-Corkum, K. Elaine Ritter, Stephen Connor Purdy, Arthur R. Wolin, Sheera R. Rosenbaum, Sabateeshan Mathavarajah, Nickerson A. Demelfi, Yueyang Wang, Yang Zhang, Mark W. Zimmerman, , Adam David Durbin

The paper identifies a core regulatory circuit in rhabdomyosarcoma and shows that targeting two co-activators synergistically inhibits tumor growth.

bioRxiv · Sep 3, 2026 · PreprintCancer Biology

Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers

Declan Bennett, Monika Wierdl, S Chakraborty, Jordan Johnson, Victoria Akingbehin, Daniel Estevez-Prado, Yuan Feng, Janeala J. Morsby, John Harper, Mohammad Ali Mohammad Nezhady, M Pan, Nicole Ocasio-Martinez, Jerrel Lewis Catlett, TB Nations, Neekesh V. Dharia, , Lillian M. Guenther

The paper develops ALTitude, a machine learning model to predict ALT status from whole genome sequencing data, identifies SMARCAL1 as a therapeutic target in ALT-driven cancers.

bioRxiv · May 28, 2026 · PreprintCancer Biology

Dominant Malignant Clones Leverage Lineage Restricted Epigenomic Programs to Drive Ependymoma Development

Alisha Kardian, Hua Sun, Siri Manasa Ippagunta, Nic Laboe, Srinidhi Varadharajan, Kwanha Yu, Hsiao‐Chi Chen, Erik Emanus, Tuyu Zheng, Riley M. Deneen, Jon P. Connelly, Yong-Dong Wang, Jiangshan Zhan, Hengxi Liu, Kimberley Lowe, , Stephen C. Mack

This study identifies specific developmental epigenomic states that enable ZFTA-RELA-driven ependymoma formation and reveals how these states shape tumor progression.

Nature · Mar 25, 2026Peer-reviewedCancer Biology

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma

Nina Weichert‐Leahey, Alla Berezovskaya, Mark W. Zimmerman, Francesca Alvarez Calderon, Marlana Winschel, Silvi Salhotra, Nathaniel W. Mabe, Antonio R. Pérez‐Atayde, Francisca N. de Luna Vitorino, Benjamin Aaron Garcia, Ulrike Gerdemann, Kimberly Stegmaier, Adam David Durbin, Derek A. Oldridge, Brian J. Abraham, Alfred Thomas Look

This study shows that inhibiting KAT6A/B with PF-9363 enhances retinoid efficacy and improves GD2-targeted immunotherapy in neuroblastoma.

bioRxiv · Jul 1, 2025 · PreprintCancer Biology